{"entity":{"id":"cctg-ce6","kind":"trial","name":"CCTG CE.6 / EORTC 26062-22061 (Perry trial)","aka":[],"tldr":"The trial that set treatment for older patients with glioblastoma: three weeks of radiotherapy instead of six, with temozolomide added, extended survival without worsening quality of life.","summary":"CCTG CE.6 with EORTC 26062-22061 and TROG 08.02, trial NCT00482677, randomised 562 patients aged 65 or older (median 73) with newly diagnosed glioblastoma to short-course radiotherapy (40 Gy in 15 fractions) with or without concurrent and adjuvant temozolomide. Median overall survival was 9.3 versus 7.6 months (HR 0.67, 95% CI 0.56-0.80) and median progression-free survival 5.3 versus 3.9 months; with a methylated MGMT promoter, 13.5 versus 7.7 months (HR 0.53), and with an unmethylated promoter 10.0 versus 7.9 months (HR 0.75, 95% CI 0.56-1.01). Quality of life was similar in the two arms. Published by Perry and colleagues in NEJM in 2017. Two earlier trials had established the alternatives for older or frail patients: the Nordic trial (Malmström 2012; temozolomide alone or hypofractionated radiotherapy at least as good as standard six-week radiotherapy over age 60, and better over 70) and NOA-08 (Wick 2012; temozolomide alone non-inferior to radiotherapy alone, with MGMT methylation predicting who benefits from temozolomide).","status":"positive","asOf":"2026-09-17","links":[{"label":"ClinicalTrials.gov NCT00482677","url":"https://clinicaltrials.gov/study/NCT00482677"},{"label":"Perry et al., Short-course radiation plus temozolomide in elderly patients with glioblastoma (NEJM 2017)","url":"https://doi.org/10.1056/NEJMoa1611977"},{"label":"Malmström et al., Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial (Lancet Oncology 2012)","url":"https://doi.org/10.1016/S1470-2045(12)70265-6"},{"label":"Wick et al., Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial (Lancet Oncology 2012)","url":"https://doi.org/10.1016/S1470-2045(12)70164-X"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["imrt-igrt"],"targets":[],"drugs":["temozolomide"],"companies":[],"institutions":[],"pathways":[],"terms":["mgmt"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00482677","phase":"3","setting":"Newly diagnosed glioblastoma, age 65 or older: short-course radiotherapy (40 Gy in 15 fractions) with concurrent and adjuvant temozolomide vs short-course radiotherapy alone","sponsor":"Canadian Cancer Trials Group / EORTC / TROG","result":"OS 9.3 vs 7.6 months, HR 0.67 (95% CI 0.56-0.80).","yearReported":2017,"enrolled":562,"outcomes":[{"endpoint":"Overall survival, age 65 or older","primary":true,"unit":"months","arms":[{"name":"Short-course RT + temozolomide","n":281,"value":9.3},{"name":"Short-course RT alone","n":281,"value":7.6}],"hr":0.67,"ci":[0.56,0.8],"p":"<0.001","source":"https://www.nejm.org/doi/full/10.1056/NEJMoa1611977"}],"replication":"Single randomised trial of adding temozolomide to short-course radiotherapy; the Nordic and NOA-08 trials support hypofractionated radiotherapy or temozolomide alone in older patients, with MGMT status guiding the choice."},"route":"/trials/cctg-ce6/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/"}],"term":[{"id":"mgmt","kind":"term","name":"MGMT promoter methylation","route":"/terms/mgmt/"}]}}